United Therapeutics Corporation (UTHR) — Business segments and KPIs
Revenue by business segment and geography for United Therapeutics Corporation, with year-over-year trends.
FY 2025
| Segment | Revenue | % of total |
|---|---|---|
| Revenue by product | ||
| Tyvaso | 1.88B | 59.0% |
| Remodulin | 526.8M | 16.6% |
| Orenitram | 496.9M | 15.6% |
| Unituxin | 226.8M | 7.1% |
| Adcirca | 30.00M | 0.9% |
| Product and Service, Other | 24.00M | 0.8% |
| Revenue by region | ||
| UNITED STATES | 3.04B | 95.4% |
| Non-US | 145.7M | 4.6% |